A Rare Case of Porto-Sinusoidal Vascular Disease Associated with Systemic Lupus Erythematosus and Antiphospholipid Syndrome.

Authors

  • Whei Chuern Yeoh Rheumatology Unit, Department of Medicine, Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia.
  • Ping Seung Ong Rheumatology Unit, Department of Medicine, Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia.

DOI:

https://doi.org/10.70672/ht7anw76

Keywords:

Antiphospholipid syndrome, cirrhosis, esophageal varices, porto-sinusoidal vascular disease, systemic lupus erythematosus.

Abstract

Porto-sinusoidal vascular disease is a medical condition characterized by increased blood pressure in the portal vein in the absence of cirrhosis. This condition is considered poorly defined because its exact cause is unknown. It has been reported to be associated with several autoimmune diseases, including systemic lupus erythematosus and antiphospholipid syndrome. We report a case of 49-year-old Indian lady with a background history of systemic lupus erythematosus with secondary antiphospholipid syndrome who was found to have esophageal varices from an esophagogastroduodenoscopy performed for iron deficiency anemia. A follow-up ultrasound and computed tomography of the abdomen confirmed the absence of cirrhosis and excluded portal vein thrombosis as a potential etiology for portal hypertension leading to the diagnosis of porto-sinusoidal vascular disease. She started on propranolol as primary prophylaxis for variceal bleeding. The patient remained well during subsequent follow-ups with the absence of new or bleeding varices during annual esophagogastroduodenoscopy surveillance. This case contributes to the further understanding of PVSD in SLE and secondary antiphospholipid syndrome. Further research is needed to enhance our understanding of its pathophysiology and to help formulate comprehensive guidelines for the effective management of this condition.

References

[1].Khanna R, Sarin SK. Non-cirrhotic portal hypertension – diagnosis and management. J Hepatol. 2014, 60(2):421-41.

[2].Yang QB, He YL, Peng CM, Qing YF, He Q, Zhou JG. Systemic lupus erythematosus complicated by noncirrhotic portal hypertension: a case report and review of literature. World J Clin Cases. 2018;6(13):688–693.

[3].Gioia S, Nardelli S, Ridola L, Riggio O. Causes and Management of Non-cirrhotic Portal Hypertension. Curr Gastroenterol Rep. 2020;22(12):56.

[4].Imabayashi K, Nakano K, Iwata S, Tanaka Y. A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension. Mod Rheumatol Case Rep. 2021;5(2):285-291.

[5].Suárez-Díaz S, García-Calonge M, Mendoza-Pacas G, Mozo-Avellaneda L, Caminal-Montero L. Non-Cirrhotic Portal Hypertension in Systemic Lupus Erythematosus. Cureus. 2023;15(2):e35494.

[6].Bessone F, Poles N, Roma MG. Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis. World J Hepatol 2014; 6(6): 394-409.

[7].Krishnan P, Fiel MI, Rosenkrantz AB, Hajdu CH, Schiano TD, Oyfe I, et al. Hepatoportal sclerosis: CT and MRI appearance with histopathologic correlation. AJR Am J Roentgenol 2012; 198: 370-376

[8].Hillaire S, Bonte E, Denninger MH, Casadevall N, Cadranel JF, Lebrec D, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002;51(2):275–280.

[9].Yamamoto M, Taniguchi H, Ohara M, Suzuki C, Naishiro Y, Ozeki I, et al. Beneficial effect of glucocorticosteroids for esophageal varices due to idiopathic portal hypertension following systemic lupus erythematosus. Nihon Rinsho Meneki Gakkai Kaishi. 2004, 27(1):40-7.

[10].Schouten JN, Nevens F, Hansen B, Laleman W, van den Born M, Komuta M, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther. 2012;35(12):1424-33.

Downloads

Published

28-05-2025

Issue

Section

Case Report

How to Cite

Whei Chuern Yeoh, & Ping Seung Ong. (2025). A Rare Case of Porto-Sinusoidal Vascular Disease Associated with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Asian Journal of Medicine & Health Sciences, 8(1). https://doi.org/10.70672/ht7anw76